Subject(s)
Antigens, Surface/metabolism , Biomarkers, Tumor/metabolism , Carcinoma, Renal Cell/diagnostic imaging , Glutamate Carboxypeptidase II/metabolism , Kidney Neoplasms/diagnostic imaging , Lysine/analogs & derivatives , Molecular Imaging/methods , Positron Emission Tomography Computed Tomography , Radiopharmaceuticals/administration & dosage , Urea/analogs & derivatives , Autopsy , Carcinoma, Renal Cell/metabolism , Carcinoma, Renal Cell/secondary , Carcinoma, Renal Cell/therapy , Cause of Death , Fatal Outcome , Humans , Kidney Neoplasms/metabolism , Kidney Neoplasms/pathology , Kidney Neoplasms/therapy , Lysine/administration & dosage , Male , Middle Aged , Predictive Value of Tests , Urea/administration & dosage , Whole Body ImagingABSTRACT
The PD-1 pathway, comprising the immune cell co-receptor Programmed Death 1 (PD-1) and its ligands, PD-L1 (B7-H1) and PD-L2 (B7-DC), mediates local immunosuppression in the tumor microenvironment. Drugs designed to block PD-1 or PD-L1 "release the brakes" on anti-tumor immunity and have demonstrated clinical activity in several types of advanced cancers, validating this pathway as a target for cancer therapy. Two such drugs have recently been approved to treat melanoma and lung cancers, and regulatory approvals in first- and second-line settings for additional cancer types are anticipated. The manageable safety profile of PD-1/PD-L1 blocking drugs identifies them as suitable for outpatient administration and the development of combinatorial therapies. Ongoing studies aim to identify biomarkers to guide patient selection, which would further improve the risk:benefit ratio for these drugs.
Subject(s)
Antineoplastic Agents/therapeutic use , B7-H1 Antigen/antagonists & inhibitors , Neoplasms/drug therapy , Programmed Cell Death 1 Receptor/antagonists & inhibitors , Biomarkers, Tumor/metabolism , Humans , Immunosuppression Therapy/methods , Neoplasms/metabolism , Tumor Microenvironment/drug effectsABSTRACT
Small renal cell carcinoma (RCC) tumors are believed to have a negligible risk of metastasis. We report on a 77-year-old man presenting with extremity weakness who was found to have a 2.5 cm brain metastasis from a subsequently discovered 1.6 cm clear cell RCC primary tumor. We review what is known about synchronous and metachronous metastasis from small renal tumors and prognostic features informing treatment for such lesions.
Subject(s)
Brain Neoplasms/diagnosis , Brain Neoplasms/secondary , Carcinoma, Renal Cell/diagnosis , Carcinoma, Renal Cell/secondary , Kidney Neoplasms/pathology , Aged , Brain Neoplasms/therapy , Carcinoma, Renal Cell/therapy , Humans , Kidney Neoplasms/surgery , Magnetic Resonance Imaging , Male , Metastasectomy , Nephrectomy , Prognosis , Radiotherapy , Tomography, X-Ray ComputedABSTRACT
PURPOSE: Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults, and radiation is one of the main treatment modalities. However, cure rates remain low despite best available therapies. Immunotherapy is a promising modality that could work synergistically with radiation, which has been shown to increase antigen presentation and promote a proinflammatory tumor microenvironment. Programmed-death-1 (PD-1) is a surface receptor expressed on activated and exhausted T cells, which mediate T cell inhibition upon binding with its ligand PD-L1, expressed on many tumor types including human GBMs. We tested the combination of anti-PD-1 immunotherapy with stereotactic radiosurgery in a mouse orthotopic GBM model. METHODS AND MATERIALS: We performed intracranial implantation of mouse glioma cell line GL261 transfected with luciferase into C57BL/6 mice. Mice were stratified into 4 treatment groups: (1) control; (2) radiation only; (3) anti-PD-1 antibody only; and (4) radiation plus anti-PD-1 antibody. Overall survival was quantified. The mice were killed on day 21 after implantation to assess immunologic parameters in the brain/tumor, cervical lymph nodes, and spleen. RESULTS: Improved survival was demonstrated with combination anti-PD-1 therapy plus radiation compared with either modality alone: median survival was 25 days in the control arm, 27 days in the anti-PD-1 antibody arm, 28 days in the radiation arm, and 53 days in the radiation plus anti-PD-1 therapy arm (P<.05 by log-rank Mantle-Cox). Long-term survival was seen only in the combined treatment arm, with a fraction (15%-40%) of animals alive at day 180+ after treatment. Immunologic data on day 21 after implantation showed increased tumor infiltration by cytotoxic T cells (CD8+/interferon-γ+/tumor necrosis factor-α+) and decreased regulatory T cells (CD4+/FOXP3) in the combined treatment group compared with the single modality arms. CONCLUSIONS: The combination of PD-1 blockade and localized radiation therapy results in long-term survival in mice with orthotopic brain tumors. These studies provide strong preclinical evidence to support combination trials in patients with GBM.
Subject(s)
Antigens, Neoplasm , B7-H1 Antigen/antagonists & inhibitors , Brain Neoplasms/therapy , Glioblastoma/therapy , Immunotherapy/methods , Radiosurgery/methods , Animals , Antigens, Neoplasm/immunology , Brain/immunology , Brain Neoplasms/immunology , Brain Neoplasms/mortality , Cell Line, Tumor , Combined Modality Therapy/methods , Combined Modality Therapy/mortality , Female , Glioblastoma/immunology , Glioblastoma/mortality , Immunotherapy/mortality , Lymph Nodes/immunology , Mice , Mice, Inbred C57BL , Neck , Radiosurgery/mortality , Spleen/immunology , Survival Analysis , T-Lymphocytes, Cytotoxic/cytology , T-Lymphocytes, Cytotoxic/immunology , T-Lymphocytes, Regulatory/cytology , T-Lymphocytes, Regulatory/immunology , Time Factors , Xenograft Model Antitumor Assays/methodsSubject(s)
Antibodies, Monoclonal, Humanized/administration & dosage , Bone Neoplasms/secondary , Carcinoma, Renal Cell/secondary , Diphosphonates/administration & dosage , Hypercalcemia/drug therapy , Imidazoles/administration & dosage , Kidney Neoplasms/pathology , Antibodies, Monoclonal/administration & dosage , Bone Neoplasms/complications , Bone Neoplasms/drug therapy , Carcinoma, Renal Cell/complications , Carcinoma, Renal Cell/pathology , Carcinoma, Renal Cell/surgery , Denosumab , Disease Progression , Drug Resistance , Fatal Outcome , Humans , Hypercalcemia/etiology , Hypercalcemia/physiopathology , Kidney Neoplasms/complications , Kidney Neoplasms/surgery , Male , Middle Aged , Parathyroid Hormone/blood , Risk Assessment , Zoledronic AcidABSTRACT
Dysregulation of the mammalian target of rapamycin and hypoxia-induced pathways has been consistently identified in clear cell renal cell carcinomas. However, experience with non-clear cell renal cell carcinoma subtypes is scant. In this study, we evaluated the immunohistochemical expression of upstream (PTEN and phosphorylated AKT) and downstream (phosphorylated S6 and 4EBP1) effectors of the mammalian target of rapamycin pathway, as well as related cell-cycle proteins (p27 and c-MYC), and a member of the hypoxia-induced pathway (HIF-1α) in 54 patients with papillary renal cell carcinoma treated by nephrectomy. PTEN was lower in tumor than in normal kidney, and loss of PTEN expression was found in 48% of the patients. In tumor tissues, phosphorylated S6, 4EBP1, and HIF-1α were higher than in normal kidney. Conversely, scores of p27 were lower in tumor than in normal kidney. Finally, scores of c-MYC and phosphorylated AKT were similar in tumor and in normal kidney. Overall mortality and cancer-specific mortality were 24% and 11%, respectively. Tumor progression was observed in 17% of the patients. None of the tested biomarkers predicted cancer-specific mortality or tumor progression. As expected, patients with high T-stage tumors had higher hazard ratios for cancer-specific mortality (hazard ratio, 6.9) and tumor progression (hazard ratio, 6.7). Patients with higher Fuhrman grades also had higher risks for cancer-specific mortality (hazard ratio, 11.4) and tumor progression (hazard ratio, 4.5). In summary, our study provides evidence of dysregulation of the mammalian target of rapamycin and hypoxia-induced pathways in papillary renal cell carcinoma. Immunohistochemistry for members of the mammalian target of rapamycin pathway and for HIF-1α lacked prognostic significance in our cohort.
Subject(s)
Biomarkers, Tumor/metabolism , Carcinoma, Papillary/metabolism , Carcinoma, Renal Cell/metabolism , Hypoxia-Inducible Factor 1, alpha Subunit/metabolism , Kidney Neoplasms/metabolism , TOR Serine-Threonine Kinases/metabolism , Adult , Aged , Aged, 80 and over , Carcinoma, Papillary/pathology , Carcinoma, Papillary/surgery , Carcinoma, Renal Cell/pathology , Carcinoma, Renal Cell/surgery , Cell Cycle Proteins/metabolism , Female , Humans , Immunohistochemistry , Kidney Neoplasms/pathology , Kidney Neoplasms/surgery , Male , Middle Aged , Nephrectomy , Phosphorylation , Prognosis , Proliferating Cell Nuclear Antigen/metabolism , Proto-Oncogene Proteins c-akt/metabolism , Tissue Array AnalysisABSTRACT
The need for effective targeted therapies for renal cell carcinomas (RCCs) has fueled the interest for understanding molecular pathways involved in the oncogenesis of kidney tumors. Aiming to analyze the expression status and prognostic significance of mTOR and hypoxia-induced pathway members in patients with clear cell RCC (ccRCC), tissue microarrays were constructed from 135 primary and 41 metastatic ccRCCs. Immunoexpression levels were compared and correlated with clinicopathologic parameters and outcome. PTEN levels were significantly lower in primary and metastatic ccRCCs compared with benign tissues (P<0.001). Levels of phos-AKT, phos-S6, and 4E-binding protein-1 (4EBP1) were higher in metastatic ccRCC (P≤0.001). For phos-S6 and 4EBP1, levels were higher in primary ccRCC compared with benign tissues (P<0.001). c-MYC levels were higher in metastatic ccRCC (P<0.0001), and incremental p27 levels were observed in benign, primary ccRCC, and metastatic ccRCC (P<0.0001). HIF-1α levels were significantly higher in primary and metastatic ccRCCs compared with benign tissues (P<0.0001). In primary ccRCC, levels of all mTOR and hypoxia-induced pathway members were significantly associated with pT stage (P≤0.036), p27 levels with Fuhrman grade (P=0.031), and 4EBP1, p27, and HIF-1α levels with tumor size (P≤0.025). Tumor size, HIF-1α, and phos-S6 levels were associated with disease-specific survival (DSS) (P≤0.032) and tumor progression (P≤0.043). In conclusion, both mTOR and hypoxia-induced pathways were activated in primary and metastatic ccRCC. PTEN loss seems to be an early event during tumorigenesis. Tumor size, HIF-1α, and phos-S6 expression were found to be independent predictors of both DSS and tumor progression in primary ccRCC.